Calcinosis in rheumatic diseases
More details
Hide details
Online publication date: 2007-04-25
Reumatologia 2007;45(2):97-101
Clacinosis occurs in damaged or devitalized tissues in the presence of normal calcium/phosphorus metabolism. It is often noted in the subcutaneous tissues in the course of connective tissues diseases – primarily systemic lupus erythematosus systemicus, sclerodermia and dermatomyositis – and may involve a relatively localized area or be widespread. The aim of the study was to discuss the classification, pathogenesis, clinical features and treatment of calcinosis in rheumatic diseases. The calcinotic accumulations may lead secondarily to muscle atrophy, join contractures and skin ulceration complicated by recurrent episodes of local inflammation and infection. Warfarin, colchicines, probenecid, bisphosphonates, diltiazem, minocycline, aluminium hydroxide, salicylate, surgical extirpation and carbon dioxide laser therapies have been used in the treatment of calcinosis. However, that kind of medication has not convincingly prevented or reduced calcinosis.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Journals System - logo
Scroll to top